🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Vandana G. Abramson

Breast Cancer Research Foundation

ORCID: 0000-0002-6855-1322

Also affiliated with Vanderbilt University, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.742Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772

Top 27%

0.742DataRank

Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Papers

Driven by 15 papers — median percentile 73. Top paper: “Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial”.

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

Annals of Oncology(2020)10.1016/j.annonc.2020.09.004

N/A

5.0DataRank · unranked

145 citations

Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy +11 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

Annals of Oncology(2023)10.1016/j.annonc.2023.08.004

N/A

1.7DataRank · unranked

58 citations

Timothy Blewett, Xun Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer

JAMA Oncology(2023)10.1001/jamaoncol.2023.5424

N/A

0.911DataRank · unranked

34 citations

Vandana G. Abramson, Elizabeth Claire Dees, Payal D. Shah, Tarah J. Ballinger, Claudine Isaacs +12 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772

Top 27%

0.742DataRank

Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07417-4

N/A

0.215DataRank · unranked

3 citations

Anne O’Neill, Ingrid A. Mayer, Carlos L. Arteaga, Ximing J. Yang, Lynne I. Wagner +17 more

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases

UNC Libraries(2020)10.17615/bgrr-9v25

N/A

0DataRank · unranked

0 citations

Anna Maria Storniolo, Vered Stearns, Vandana G. Abramson, Joel S. Parker, Catherine Van Poznak +19 more

Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer

International Journal of Molecular Sciences(2021)10.3390/ijms22105207

N/A

0DataRank · unranked

73 citations

Jinming Yang, Nabil Saleh, Sheau‐Chiann Chen, Gregory D. Ayers, Vandana G. Abramson +3 more

A Randomized Clinical Trial of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention

medRxiv(2021)10.1101/2021.10.12.21264773

N/A

0DataRank · unranked

7 citations

Mary S. Dietrich, John Boyages, Louise Koelmeyer, Elisabeth Elder, Michael Hughes +7 more

Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.525

N/A

0DataRank · unranked

0 citations

Lauren Lenz, Elizabeth S. Cogan, Erica L. Mayer, Virginia Kaklamani, Vered Stearns +15 more

NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0519

N/A

0DataRank · unranked

65 citations

Xiaopeng Sun, Paula I. González-Ericsson, Violeta Sánchez, Melinda E. Sanders, Elizabeth C. Wescott +15 more

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Research Square(2024)10.21203/rs.3.rs-4295044/v1

N/A

0DataRank · unranked

0 citations

Anne O’Neill, Ingrid A. Mayer, Carlos L. Arteaga, Ximing J. Yang, Lynne I. Wagner +17 more

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3685

N/A

0DataRank · unranked

60 citations

Mellissa J. Nixon, Paula I. González-Ericsson, Riley E. Bergman, Mark A. Pilkinton, Wyatt J. McDonnell +21 more

Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy

Breast Cancer Research and Treatment(2020)10.1007/s10549-020-05846-5

N/A

0DataRank · unranked

6 citations

Caroline A. Nebhan, Jinming Yang, Lauren S. Starnes, Chi Yan, Anna E. Vilgelm +6 more

Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer

Tomography(2020)10.18383/j.tom.2020.00002

N/A

0DataRank · unranked

3 citations

Jason M. Williams, Hakmook Kang, Lori R. Arlinghaus, Richard G. Abramson, Vandana G. Abramson +4 more

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps1102

N/A

0DataRank · unranked

10 citations

Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisín M. Connolly, Erin Roesch, Anosheh Afghahi +15 more